Neonates have immature liver enzyme systems, which impacts the metabolism of phenytoin. This immaturity can lead to prolonged drug half-life and increased risk of toxicity. Therefore, careful monitoring of serum levels is necessary. The drug's metabolism can also be affected by factors such as concurrent medications and the neonate's overall health status.
